These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
553 related articles for article (PubMed ID: 21825258)
1. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. Marchetti A; Felicioni L; Malatesta S; Grazia Sciarrotta M; Guetti L; Chella A; Viola P; Pullara C; Mucilli F; Buttitta F J Clin Oncol; 2011 Sep; 29(26):3574-9. PubMed ID: 21825258 [TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations. Tissot C; Couraud S; Tanguy R; Bringuier PP; Girard N; Souquet PJ Lung Cancer; 2016 Jan; 91():23-8. PubMed ID: 26711930 [TBL] [Abstract][Full Text] [Related]
3. Clinicopathological features of nonsmall cell lung carcinomas with BRAF mutations. Kinno T; Tsuta K; Shiraishi K; Mizukami T; Suzuki M; Yoshida A; Suzuki K; Asamura H; Furuta K; Kohno T; Kushima R Ann Oncol; 2014 Jan; 25(1):138-42. PubMed ID: 24297085 [TBL] [Abstract][Full Text] [Related]
4. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644 [TBL] [Abstract][Full Text] [Related]
5. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910 [TBL] [Abstract][Full Text] [Related]
6. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320 [TBL] [Abstract][Full Text] [Related]
7. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Cardarella S; Ogino A; Nishino M; Butaney M; Shen J; Lydon C; Yeap BY; Sholl LM; Johnson BE; Jänne PA Clin Cancer Res; 2013 Aug; 19(16):4532-40. PubMed ID: 23833300 [TBL] [Abstract][Full Text] [Related]
8. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288 [TBL] [Abstract][Full Text] [Related]
9. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients. Bhaumik S; Ahmad F; Das BR Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917 [TBL] [Abstract][Full Text] [Related]
10. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations. Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121 [TBL] [Abstract][Full Text] [Related]
11. Molecular alterations in non-small cell lung carcinomas of the young. VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236 [TBL] [Abstract][Full Text] [Related]
12. V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics. Salimian KJ; Fazeli R; Zheng G; Ettinger D; Maleki Z Acta Cytol; 2018; 62(2):79-84. PubMed ID: 29320776 [TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation. Ding X; Zhang Z; Jiang T; Li X; Zhao C; Su B; Zhou C Cancer Med; 2017 Mar; 6(3):555-562. PubMed ID: 28135039 [TBL] [Abstract][Full Text] [Related]
14. Natural Disease History, Outcomes, and Co-mutations in a Series of Patients With BRAF-Mutated Non-small-cell Lung Cancer. Myall NJ; Henry S; Wood D; Neal JW; Han SS; Padda SK; Wakelee HA Clin Lung Cancer; 2019 Mar; 20(2):e208-e217. PubMed ID: 30442523 [TBL] [Abstract][Full Text] [Related]
15. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study. Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417 [TBL] [Abstract][Full Text] [Related]
16. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079 [TBL] [Abstract][Full Text] [Related]
17. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. Sacher AG; Dahlberg SE; Heng J; Mach S; Jänne PA; Oxnard GR JAMA Oncol; 2016 Mar; 2(3):313-20. PubMed ID: 26720421 [TBL] [Abstract][Full Text] [Related]
18. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. Hirsch FR; Varella-Garcia M; Bunn PA; Franklin WA; Dziadziuszko R; Thatcher N; Chang A; Parikh P; Pereira JR; Ciuleanu T; von Pawel J; Watkins C; Flannery A; Ellison G; Donald E; Knight L; Parums D; Botwood N; Holloway B J Clin Oncol; 2006 Nov; 24(31):5034-42. PubMed ID: 17075123 [TBL] [Abstract][Full Text] [Related]
19. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758 [TBL] [Abstract][Full Text] [Related]
20. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]